The American Heart Association estimates that about half of all Americans suffer from cardiovascular disease (CVD), which is a collection of conditions that includes atrial fibrillation, heart failure, strokes, and heart valve disease. It is now a difficult but vital duty to guarantee that these millions of people can receive the care and treatments they require.
Following their admission to a healthcare network, patients must be followed up with and assigned to appropriate treatment throughout time.
Let’s introduce Egnite, a digital healthcare startup based in California that uses artificial intelligence (AI) to support doctors in making sure patients have quicker access to the necessary medications. With the help of the company’s patented technologies, medical professionals can gain a deeper understanding of their cardiovascular patients by tracking the length of time since a diagnosis and identifying those who require the most attention from their physicians. These technologies analyze enormous data sets comprising millions of electronic medical records and charts.
Over fifty US healthcare systems use CardioCare, the company’s flagship technology, to help identify patients with cardiovascular illnesses who might not receive treatment. For patients with CVD, CardioCare identifies the helpful information that may be the difference between life and death.
According to Egnite’s chief product officer, Kahla Verhoef, CardioCare can increase life-saving treatments by an average of up to 25%. “We partner with health systems to get patients off the sidelines and connected with specialists who are qualified to make decisions about their care,” says Verhoef.
These kinds of discoveries are crucial to medicine, as healthcare innovation is an iterated process. In medical terms, collaboration with AI is necessary for improvement as treatments improve and understanding grows.